Archives

BGM0504 Achieves 19.3% Robust Weight Reduction, 16.5 cm Waist Circumference Decrease, Significant SBP/DBP Improvements of 22.9/12.9 mmHg, and 70.7 μmol/L Uric Acid Reduction; Phase III Trial Meets Primary Endpoint and All Key Secondary Endpoints

B SUZHOU, China, May 5, 2026 /PRNewswire/ — BrightGene Bio-Medical Technology Co., Ltd. (hereinafter referred to as ” BrightGene Bio-Medical” or “the Company”) announced that… Login to continue reading Login…

Read MoreBGM0504 Achieves 19.3% Robust Weight Reduction, 16.5 cm Waist Circumference Decrease, Significant SBP/DBP Improvements of 22.9/12.9 mmHg, and 70.7 μmol/L Uric Acid Reduction; Phase III Trial Meets Primary Endpoint and All Key Secondary Endpoints

Global Millennial Capital Raises USD 100 Million to Fund New-Age Technology Leaders in Underpenetrated Mid-Cap Segments

B GMCL’s IPO Opportunities Fund targets investments in AI, decentralized finance technologies and new-age energy solutions in companies with a market capitalization between USD 5… Login to continue reading Login…

Read MoreGlobal Millennial Capital Raises USD 100 Million to Fund New-Age Technology Leaders in Underpenetrated Mid-Cap Segments

Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn’s disease

B TREMFYA® demonstrated significantly higher rates of combined fistula remission – complete external closure of draining fistulas and absence of fluid collection on MRI –… Login to continue reading Login…

Read MoreJohnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn’s disease